Product Images Donepezil Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 15 images provide visual information about the product associated with Donepezil Hydrochloride NDC 68788-8208 by Preferred Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
This is a description of a medication called Donepezil HCI Tablets 5mg, which is the generic brand of Aricept. The tablets are prescribed for patients suffering from certain medical conditions. The description includes information on the manufacturer, package size, lot number, expiration date, and warning on keeping the medication out of reach of children. There is also a mention of a billing chart log, likely for record-keeping purposes.*
This is a graph that shows the cumulative percentage of patients who were given either 10 mg/day of donepezil hydrochloride or a placebo drug. The X-axis displays the change in ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living) from baseline, while the Y-axis shows the percentage of patients who showed improvement or decline. The line representation of donepezil is marked with "e" and the placebo with "o". The graph indicates that donepezil hydrochloride performed better than placebo in terms of the percentage of patients who experienced improvement.*
The text appears to be a graph or chart without any labels, titles, or context. It is not possible to provide a useful description with only this information.*
This is a table displaying the results of a clinical trial for Donepezil Hydrochloride, a medication used to treat Alzheimer's disease. The table shows the percentage of patients who showed improvement in their CIBIC-plus Rating, a measure of cognitive and functional ability, after taking either Donepezil Hydrochloride or a placebo. The table also shows the level of improvement (moderately, minimally, or markedly) and the percentage of patients who got worse.*
This text represents a chart or graph showing the change in SIB (Severe Impairment Battery) scores from baseline, with mean values and standard error for patients treated with donepezil hydrochloride 10 mg/day and those treated with a placebo, after 3 months of drug treatment. The chart suggests that donepezil hydrochloride treatment may lead to clinical improvement in patients with the condition being studied.*
This is a graph showing the cumulative percentage of patients on Donepezil Hydrochloride 10mg/day and Placebo. The SIB (Severe Impairment Battery) change from the baseline is also shown on the graph in percentages. The X-axis of the graph measures the time in weeks while the Y-axis shows the percentage change.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.